The estimated Net Worth of Thomas H. Tulip is at least $45 dollars as of 15 March 2013. Thomas Tulip owns over 17,500 units of Navidea Biopharmaceuticals Inc stock worth over $45 and over the last 13 years Thomas sold NAVB stock worth over $0.
Thomas has made over 2 trades of the Navidea Biopharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Thomas bought 17,500 units of NAVB stock worth $49,350 on 15 March 2013.
The largest trade Thomas's ever made was buying 17,500 units of Navidea Biopharmaceuticals Inc stock on 15 March 2013 worth over $49,350. On average, Thomas trades about 4,063 units every 23 days since 2011. As of 15 March 2013 Thomas still owns at least 45,000 units of Navidea Biopharmaceuticals Inc stock.
You can see the complete history of Thomas Tulip stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is 5600 BLAZER PARKWAY, SUITE 200, DUBLIN, OH, US 43017.
Over the last 13 years, insiders at Navidea Biopharmaceuticals Inc have traded over $3,167,813 worth of Navidea Biopharmaceuticals Inc stock and bought 7,718,496 units worth $6,241,151 . The most active insiders traders include John K Jr. Scott, Perry A Karsen et Life Sciences, Llc Platinum.... On average, Navidea Biopharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $159. The most recent stock trade was executed by John K Jr. Scott on 10 April 2022, trading 3,260 units of NAVB stock currently worth $3.
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Navidea Biopharmaceuticals Inc executives and other stock owners filed with the SEC include: